Novel Antiplatelet Therapies for Atherothrombotic Diseases

Overview

Journal Arterioscler Thromb Vasc Biol

Date 2019 Feb 15

PMID 30760019

Citations 28

Authors

Arjun Majithia

Deepak L Bhatt

Affiliations

Soon will be listed here.

Abstract

Antiplatelet therapies are an essential tool to reduce the risk of developing clinically apparent atherothrombotic disease and are a mainstay in the therapy of patients who have established cardiovascular, cerebrovascular, and peripheral artery disease. Strategies to intensify antiplatelet regimens are limited by concomitant increases in clinically significant bleeding. The development of novel antiplatelet therapies targeting additional receptor and signaling pathways, with a focus on maintaining antiplatelet efficacy while preserving hemostasis, holds tremendous potential to improve outcomes among patients with atherothrombotic diseases.

Citing Articles

Incidence of bleeding during and after two non-surgical periodontal therapy schemes in patients with recent acute coronary syndrome on dual antiplatelet therapy: A pilot study.

Moscoso S, Mendoza F, Gomez L, Londono A, Marin J, Sarmiento J J Clin Exp Dent. 2025; 16(12):e1495-e1502.

PMID: 39822789 PMC: 11733894. DOI: 10.4317/jced.61758.

Demographic diversity in platelet function and response to antiplatelet therapy.

Jain K, Tyagi T, Gu S, Faustino E, Hwa J Trends Pharmacol Sci. 2024; 46(1):78-93.

PMID: 39672782 PMC: 11710996. DOI: 10.1016/j.tips.2024.11.005.

Role of Thrombosis in Neurodegenerative Diseases: An Intricate Mechanism of Neurovascular Complications.

Beura S, Panigrahi A, Yadav P, Kulkarni P, Lakhanpal V, Singh B Mol Neurobiol. 2024; 62(4):4802-4836.

PMID: 39482419 DOI: 10.1007/s12035-024-04589-4.

Inhibiting the P2Y Receptor in Megakaryocytes and Platelets Suppresses Interferon-Associated Responses.

Sowa M, Sun H, Wang T, Virginio V, Schlamp F, El Bannoudi H JACC Basic Transl Sci. 2024; 9(9):1126-1140.

PMID: 39444926 PMC: 11494392. DOI: 10.1016/j.jacbts.2024.05.014.

Non-ST Elevation Myocardial Infarction in the Elderly. Antithrombotic Therapy and Beyond.

Diez-Villanueva P, Jimenez-Mendez C, Ferreiro J, Cepas-Guillen P, Bonanad C, Garcia-Blas S Rev Cardiovasc Med. 2024; 24(7):201.

PMID: 39077013 PMC: 11266491. DOI: 10.31083/j.rcm2407201.

References

Laurent P, Severin S, Hechler B, Vanhaesebroeck B, Payrastre B, Gratacap M . Platelet PI3Kβ and GSK3 regulate thrombus stability at a high shear rate. Blood. 2014; 125(5):881-8. DOI: 10.1182/blood-2014-07-588335. View

Flaumenhaft R, Furie B, Zwicker J . Therapeutic implications of protein disulfide isomerase inhibition in thrombotic disease. Arterioscler Thromb Vasc Biol. 2014; 35(1):16-23. PMC: 4270882. DOI: 10.1161/ATVBAHA.114.303410. View

Vaduganathan M, Bhatt D . Simultaneous Platelet P2Y12 and P2Y1 ADP Receptor Blockade: Are Two Better Than One?. Arterioscler Thromb Vasc Biol. 2016; 36(3):427-8. DOI: 10.1161/ATVBAHA.115.307097. View

Gaziano J, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick P . Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018; 392(10152):1036-1046. PMC: 7255888. DOI: 10.1016/S0140-6736(18)31924-X. View

Li J, Vootukuri S, Shang Y, Negri A, Jiang J, Nedelman M . RUC-4: a novel αIIbβ3 antagonist for prehospital therapy of myocardial infarction. Arterioscler Thromb Vasc Biol. 2014; 34(10):2321-9. PMC: 4180209. DOI: 10.1161/ATVBAHA.114.303724. View

Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C . Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013; 369(1):11-9. DOI: 10.1056/NEJMoa1215340. View

Sturgeon S, Jones C, Angus J, Wright C . Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat. Eur J Pharmacol. 2008; 587(1-3):209-15. DOI: 10.1016/j.ejphar.2008.03.017. View

Yusuf S, Zhao F, Mehta S, Chrolavicius S, Tognoni G, Fox K . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345(7):494-502. DOI: 10.1056/NEJMoa010746. View

Steg P, Bhatt D, Hamm C, Stone G, Gibson C, Mahaffey K . Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2013; 382(9909):1981-92. DOI: 10.1016/S0140-6736(13)61615-3. View

10.

McNeil J, Wolfe R, Woods R, Tonkin A, Donnan G, Nelson M . Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med. 2018; 379(16):1509-1518. PMC: 6289056. DOI: 10.1056/NEJMoa1805819. View

11.

Gremmel T, Yanachkov I, Yanachkova M, Wright G, Wider J, Undyala V . Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis. Arterioscler Thromb Vasc Biol. 2016; 36(3):501-9. PMC: 4767596. DOI: 10.1161/ATVBAHA.115.306885. View

12.

McFadyen J, Schaff M, Peter K . Current and future antiplatelet therapies: emphasis on preserving haemostasis. Nat Rev Cardiol. 2018; 15(3):181-191. DOI: 10.1038/nrcardio.2017.206. View

13.

Bhatt D, Bonaca M, Bansilal S, Angiolillo D, Cohen M, Storey R . Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. J Am Coll Cardiol. 2016; 67(23):2732-2740. DOI: 10.1016/j.jacc.2016.03.529. View

14.

Cavallari L, Lee C, Beitelshees A, Cooper-DeHoff R, Duarte J, Voora D . Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2017; 11(2):181-191. PMC: 5775044. DOI: 10.1016/j.jcin.2017.07.022. View

15.

Nylander S, Kull B, Bjorkman J, Ulvinge J, Oakes N, Emanuelsson B . Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor. J Thromb Haemost. 2012; 10(10):2127-36. DOI: 10.1111/j.1538-7836.2012.04898.x. View

16.

Sawlani N, Harrington R, Stone G, Steg P, Gibson C, Hamm C . Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2017; 10(1). DOI: 10.1161/CIRCINTERVENTIONS.116.004380. View

17.

Bach P, Antonsson T, Bylund R, Bjorkman J, Osterlund K, Giordanetto F . Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283. J Med Chem. 2013; 56(17):7015-24. DOI: 10.1021/jm400820m. View

18.

Mohamed O, Al-Masri A, El Eter E, Lateef R . SCH 79797, a selective PAR1 antagonist, protects against ischemia/reperfusion-induced arrhythmias in the rat hearts. Eur Rev Med Pharmacol Sci. 2016; 20(22):4796-4800. View

19.

Baber U, Dangas G, Cohen D, Gibson C, Mehta S, Angiolillo D . Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. Am Heart J. 2016; 182:125-134. DOI: 10.1016/j.ahj.2016.09.006. View

20.

Harrington R, Stone G, McNulty S, White H, Lincoff A, Gibson C . Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009; 361(24):2318-29. DOI: 10.1056/NEJMoa0908628. View